NA808 PhaseI multiple ascending doses study

PhaseI study with multiple, ascending doses of NA808 in patients with chronic hepatitis C viral infection.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221056

Enrollment

Registered

2010-04-05

Start date

2010-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic hepatitis C viral infection

Interventions

investigational material(s) Generic name etc : NA808 INN of investigational material : Therapeutic category code : 639 Other biological preparations Dosage and Administration for Investigational mate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subject shows detectable HCV RNA and has no clinically significant disorders. Male or female of no child-bearing potential

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Safety Pharmacokinetics HCV-RNA viral kinetics	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026